Abstract: A novel process for the preparation of .alpha.-substituted arylacetamides wherein the substituent is an aromatic group or a 1-alkenyl or 1-cycloalkenyl group and wherein the nitrogen atom carries no hydrogen atoms comprises the reaction of an arylacetamide having one or two hydrogen atoms on the .alpha.-carbon atom, wherein the nitrogen atom carries no hydrogen atoms, with a strong base in an inert aprotic organic solvent, followed by reaction with a zerovalent transition metal catalyst and then with a compound of the formula R.sup.4 --X, wherein R.sup.4 is selected from aromatic groups, 1-alkenyl groups and 1-cycloalkenyl groups and X is a particular leaving group, especially a triflate group. The .alpha.-substituted arylacetamides are useful as intermediates in the preparation (by reduction) of .alpha.-substituted arylethylamines, e.g., 1-substituted-2,3,4,5-tetrahydro-1H-3-benzazepines, having pharmacological activity. Certain benzazepines wherein the 1-substituent R.sup.4 is 1-(1-cycloalkenyl) are novel.

Abstract: A novel process for regioselectively preparing oxazoline compounds is disclosed. The process utilizes an amino alcohol, a cyano compound, a base and a dihydric alcohol solvent, a polyhydric alcohol solvent or mixtures thereof.

Abstract: Heterobicyclic and heterocyclic intermediate compounds and their use in treating inflammation, hyperproliferative skin conditions such as psoriasis and allergy are disclosed.

Abstract: The present invention relates to a process for preparing bicyclic compounds and intermediates thereof. The compounds are useful as anti-allergic, anti-inflammatory and/or cytoprotective agents.

Abstract: The present invention relates to a monoclonal antibody-and to the hybridoma that produces it-specific for a surface antigen of activated B cells and T cells transformed by the virus HTLV-I. The hybridoma has been deposited with the European Collection of Annimal Cell Cultures (ECACC) under the number 88062301.

Abstract: A method for dehalogenating a compound of the generalized structure ##STR1## is disclosed where: R.sub.1, R.sub.2 and R.sub.3 independently are hydrogen or methyl or R.sub.1 and R.sub.3 taken together represent methylene, with the proviso that R.sub.1, R.sub.2 and R.sub.3 are not all methyl;X is a halogen;m is zero, 1 or 2; andY is a pharmaceutically acceptable acid.The method comprises contacting compound I with a catalytic hydrogenolysis system to replace the halogen with a hydrogen. A particularly preferred hydrogenolysis system comprises Pd/C and ammonium formate.

Abstract: The invention describes a kit and a method useful for analyzing the plasma concentration of an active neuroleptic drug known to have D-1 receptor antagonist properties utilizing labeled [-]trans 6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo[d]naphtho-[2 ,1-b]-azepine.

Abstract: Biologically active, enantiomerically substantially pure intermediates of trans-hexahydro-benzo[d]naphtho[2,1-b]azepines are prepared.The present invention involves a process for preparing compounds of the general formula 3: ##STR1## wherein: R* is ##STR2## Each R.sup.1 is independently H or alkyl; Q is methylene, --O-- or --S--;m and n are independently variable and may each have a value of 0, 1 or 2, with the provisos that the sum of m and n is not greater than 3, that m may not equal zero when Q is --O-- or --S--, and that when Q is --CH.sub.2 --, m and n cannot both be zero;X is hydrogen, halo, alkyl, alkylthio, alkylsulfinyl, alkylsufonyl, hydroxy, alkoxy or trifluoromethyl;Y is hydrogen, hydroxy, alkoxy, --OC(O)NR.sup.2 R.sup.3, --OC(O)--R.sup.9, --N(R.sup.1).sub.2, --NHC(O)R.sup.1 or --OP(O)(OH)OR.sup.1,R.sup.2 and R.sup.3 are the same or different and each is hydrogen (provided that both are not hydrogen), alkyl, aralkyl, cycloalkyl, aryl, hydroxyalkyl, or alkoxyalkyl;in addition, when one of R.sup.

Abstract: There is disclosed a process for preparing a compound represented by the formula ##STR1## where P is hydrogen.

Abstract: Imidazo- and pyrimido-quinoline, naphthyridine and pyridopyrazine compounds, methods of making said compounds and their use as anti-allergy, antiinflammatory and/or agents for the treatment of hyperproliferative skin disease are disclosed.

Abstract: This invention relates to tri- and tetra-substituted-oxetanes, e.g. (.+-.)-cis- and (.+-.)-trans-2-[(4-(4-isopropylpiperazin-1-yl)phenoxy)methyl]-4-(2,4-dihal ophenyl)-4-[1H-1,2,4-triazol-1-yl)-methyl]oxetane and tri- and tetra-substituted-tetrahydrofurans, e.g. (.+-.)-cis- and (.+-.)-trans-1-[4-[[2-(2,4-dihalophenyl)tetrahydro-2-[(1H-azol-1-yl)methyl ]-5-furanylmethoxy]phenyl]-4-yl-1-substituted piperazine-3-one and related derivatives which exhibit antifungal and antiallergy activities, pharmaceutical composition thereof, methods of their use in treating or preventing susceptible fungal infections and allergic reactions in a host including warm-blooded animals such as humans.

Abstract: A method for producing a compound of the formula ##STR1## wherein: R.sup.1, R.sup.11 and R.sup.12 may be the same or different and each is hydrogen or alkyl;Q is methylene, --O-- or --S--;m and n are independently variable and may each have a value of 0, 1 or 2;X is hydrogen, halo, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, hydroxy, alkoxy or trifluoromethyl;Y is hydrogen, hydroxy, alkoxy, ##STR2## --N(R.sup.1).sub.2, ##STR3## where R.sup.1 is as defined above; ring t represents a fused thiophene or fused benzene ring, said fused benzene ring optionally being substituted with a substituent Z as defined below; andZ is X as defined above, amino, alkylamino or ##STR4## {wherein R.sup.10 is hydrogen, alkyl or aryl}, comprising reacting a compound of formula II or formula III ##STR5## with a compound of the formula where Hal is a halogen; andR.sup.13 is acetyl, or Si(R.sup.14).sub.3 where each R.sup.14 independently is alkyl or aryl is disclosed.

Abstract: Isoquinolinone and isothiochromone derivatives of the general formula ##STR1## are disclosed. These compounds display anti-allergy, antiinflammatory and anti-hyperproliferative activity, which makes them useful for treating related disorders.

Abstract: An improved method for producing a hydrotreated oil from a naphthenic feed is described. The process comprises passing the naphthenic feed through the multistage hydrotreating process with intermediate removal of hydrogen sulfide and/or ammonia.

Abstract: A wax-containing petroleum distillate fuel composition having improved low temperature flow properties is described. The distillate fuel has added thereto:A. an amorphous, normally solid, essentially saturated hydrocarbon fraction substantially free of normal paraffin hydrocarbons;B. a wax modifying random copolymer of ethylene and an unsaturated ester; andC. an ether.

Abstract: An asphaltic composition having improved temperature susceptibility and a method of manufacturing the improved asphaltic composition are disclosed. The improvement is directed at the addition of a stabilizing agent selected from the group consisting of Group IA sulfates, Group IIB sulfates and mixtures thereof.

Abstract: A lube oil and method of making same having improved anti-wear properties is described. The lube oil comprises:A. a basestock;B. a diphenyl carbonate; andC. a metal dialkyldithiophosphate salt.

Abstract: A hydrocarbon chargestock (11) is separated by distillation (12, 16), e.g. at least in part under reduced pressure, into a conversion feedstream (22, 24) and a vacuum residuum (17). The feedstream is converted at an elevated temperature in a conversion unit (25), e.g. a fluidized catalytic cracking system, to high temperature conversion products (26) which are passed into the bottom region of the lower portion (27) of a fractionation tower (28). The vacuum residuum (17) is passed (via 50) into the top of the lower portion (27) of the fractionation tower (28).

Abstract: A method and apparatus for passivating the adverse catalytic effects of metal contaminated hydrocarbon feedstocks is described. The method is directed at the use of control means to regulate the residence time of the catalyst in the passivation zone and to regulate the reducing gas flow rate to the passivation zone.

Abstract: A method and apparatus for improving the separation of a distillation system comprising a main distillation zone and at least one sidestream separation zone is described. The method comprises returning vapor separated in the sidestream separation zone to the main distillation zone at a location at least two trays and/or at least one theoretical stage above the liquid draw-off from the main distillation zone to the sidestream separation zone.